MK-0493
MK-0493
MK-0493 is an investigational drug that was developed by Merck & Co. as a potential treatment for type 2 diabetes mellitus. It is classified as a melanin-concentrating hormone receptor 1 antagonist (MCHr1 antagonist), which means it works by blocking the action of the melanin-concentrating hormone (MCH) at its receptor site.
Mechanism of Action[edit | edit source]
MK-0493 functions by inhibiting the MCHr1, a receptor that is involved in the regulation of energy homeostasis and body weight. MCH is a neuropeptide that plays a role in increasing appetite and promoting energy storage. By blocking this receptor, MK-0493 was hypothesized to reduce appetite and promote weight loss, which could be beneficial in managing type 2 diabetes, a condition often associated with obesity.
Clinical Development[edit | edit source]
MK-0493 underwent several phases of clinical trials to evaluate its efficacy and safety in humans. Initial studies focused on its potential to aid in weight loss and improve glycemic control in patients with type 2 diabetes. However, despite promising preclinical data, the clinical trials did not demonstrate sufficient efficacy in achieving the desired therapeutic outcomes. As a result, the development of MK-0493 was eventually discontinued.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of MK-0493 was studied to understand its absorption, distribution, metabolism, and excretion (ADME) characteristics. The drug was found to have a suitable half-life for once-daily dosing, but specific details regarding its metabolism and excretion pathways were not extensively published due to the discontinuation of its development.
Safety and Tolerability[edit | edit source]
In clinical trials, MK-0493 was generally well-tolerated, with a safety profile similar to other drugs in its class. Common adverse effects included mild gastrointestinal symptoms and transient increases in liver enzymes. No serious adverse events directly attributable to MK-0493 were reported in the published data.
Discontinuation[edit | edit source]
The development of MK-0493 was halted after clinical trials failed to show significant benefits over existing treatments for type 2 diabetes. The decision to discontinue was based on a comprehensive evaluation of the drug's efficacy, safety, and market potential.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
